Page last updated: 2024-12-06

rpr 103611

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RPR 103611: a statine derivative; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72411
CHEMBL ID7447
MeSH IDM0259102

Synonyms (16)

Synonym
rpr 103611
(3s,4s)-4-[8-[[(1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-hydroxy-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carbonyl]amino]octanoylamino]-3-hydroxy-6-methyl-heptanoic acid
rpr103611
150840-75-8
heptanoic acid, 3-hydroxy-4-[[8-[[(3.beta.)-3-hydroxy-28-oxolup-20(29)-en-28-yl]amino]-1-oxooctyl]amino]-6-methyl-, (3s,4s)-
CHEMBL7447
(3s,4s)-4-[8-[[(1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carbonyl]amino]octanoylamino]-3-hydroxy-6-methylheptanoic acid
heptanoic acid, 3-hydroxy-4-((8-(((3-beta)-3-hydroxy-28-oxolup-20(29)-en-28-yl)amino)-1-oxooctyl)amino)-6-methyl-, (s-(r*,r*))-
(s-(r*,r*))-3-hydroxy-4-((8-(((3-beta)-3-hydroxy-28-oxolup-20(29)-en-28-yl)amino)-1-oxooctyl)amino)-6-methylheptanoic acid
n'-(n-(3-hydroxylup-20(29)-en-28-oyl)-8-aminooctanoyl)-4-amino-3-hydroxy-6-methylheptanoic acid
heptanoic acid, 3-hydroxy-4-((8-(((3beta)-3-hydroxy-28-oxolup-20(29)-en-28-yl)amino)-1-oxooctyl)amino)-6-methyl-, (s-(r*,r*))-
(s-(r*,r*))-3-hydroxy-4-((8-(((3beta)-3-hydroxy-28-oxolup-20(29)-en-28-yl)amino)-1-oxooctyl)amino)-6-methylheptanoic acid
rpr-103611
4-[(8-{[3,28-dihydroxylup-20(29)-en-28-ylidene]amino}-1-hydroxyoctylidene)amino]-3-hydroxy-6-methylheptanoic acid
DTXSID10934100
HY-146338
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1873270Antiviral activity against HIV-1 YU2 (R4) infected in human TZM-bl cells assessed as reduction in viral replication2022Bioorganic & medicinal chemistry letters, 08-01, Volume: 69Design, synthesis, and bio-evaluation of novel triterpenoid derivatives as anti-HIV-1 compounds.
AID78783Toxic concentration on HIV-1 mock infected H9 lymphocyte cells1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents.
AID1873273Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability by CellTitre-Glo assay2022Bioorganic & medicinal chemistry letters, 08-01, Volume: 69Design, synthesis, and bio-evaluation of novel triterpenoid derivatives as anti-HIV-1 compounds.
AID81588full Inhibitory activity against HIV-1-induced syncytia1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents.
AID1873272Antiviral activity against HIV-1 89.6 infected in human TZM-bl cells assessed as reduction in viral replication2022Bioorganic & medicinal chemistry letters, 08-01, Volume: 69Design, synthesis, and bio-evaluation of novel triterpenoid derivatives as anti-HIV-1 compounds.
AID78942Inhibitory activity against HIV-1 replication in mock infected H9 cells1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents.
AID1873274Selectivity index, ratio of CC50 for human TZM-bl cells to IC50 for IC50 for antiviral activity against HIV-1 89.6 infected in human TZM-bl cells2022Bioorganic & medicinal chemistry letters, 08-01, Volume: 69Design, synthesis, and bio-evaluation of novel triterpenoid derivatives as anti-HIV-1 compounds.
AID1873271Antiviral activity against HIV-1 NL4-3(X4) infected in human TZM-bl cells assessed as reduction in viral replication2022Bioorganic & medicinal chemistry letters, 08-01, Volume: 69Design, synthesis, and bio-evaluation of novel triterpenoid derivatives as anti-HIV-1 compounds.
AID1706898Anti-HIV-1 activity against HIV1 IIIB infected in human H9 cells assessed as in p24 antigen production by sandwich ELISA2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Triterpenoid-Mediated Inhibition of Virus-Host Interaction: Is Now the Time for Discovering Viral Entry/Release Inhibitors from Nature?
AID198243Inhibitory activity against HIV-RT; no inhibition1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (42.86)18.2507
2000's2 (28.57)29.6817
2010's0 (0.00)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.62 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]